Rapamycin, acarbose and 17α-estradiol preserved trabecular bone in ageing female UM-HET3 mice
In UM-HET3 mice, lifespan-extending doses of rapamycin, acarbose or 17α-estradiol were linked to trabecular bone responses in females at 22 months, mainly more trabeculae; effects in males were generally negligible. This is mouse data, not evidence of human bone or lifespan benefit. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract describes examining long-term effects of rapamycin, acarbose and 17α-estradiol at lifespan-extending doses on trabecular and cortical bone in male and female UM-HET3 mice, measured at 12 and 22 months. [1]
All three interventions produced trabecular bone responses in females at 22 months, driven mainly by increases in trabecular number, while treatment effects in males were generally negligible. [1]
The strongest skeletal responses in females contrast with the predominantly male-biased lifespan extension reported for acarbose and 17α-estradiol, suggesting different mechanisms. [1]
The source at a glance
- Study type / format
- Preclinical mouse study (abstract).
- Population / context
- Male and female UM-HET3 mice measured at 12 and 22 months of age.
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- June 19, 2026
Bone ageing in UM-HET3 mice given geroprotectors
The abstract notes that geroprotectors extend lifespan and improve several aspects of healthspan, but their effects on skeletal ageing remain poorly understood. The authors suggest such drugs might also improve bone, neuromuscular function and vision, potentially reducing falls, a major cause of fractures. They describe examining long-term effects of rapamycin, acarbose and 17α-estradiol at lifespan-extending doses on trabecular and cortical bone in male and female UM-HET3 mice, calling this the first such examination.
Supporting source [1]
More trabeculae in females at 22 months
Bone architecture was measured with micro–computed tomography at 12 and 22 months of age. A Bayesian modelling analysis found that all three interventions produced responses in trabecular bone in females at 22 months. These effects were driven mainly by increases in trabecular number, with little evidence for changes in trabecular thickness. In males, treatment effects were generally negligible. Cortical responses were modest: cortical area fraction rose moderately in females given rapamycin or 17α-estradiol at 22 months, while cortical thickness remained largely unchanged, suggesting a geometrical rather than anabolic effect.
Supporting source [1]
Sex difference versus male-biased lifespan findings
The authors highlight that the strongest skeletal responses to geroprotectors occurred in females, which contrasts with the predominantly male-biased lifespan extension reported for acarbose and 17α-estradiol. They interpret this as suggesting different mechanisms may mediate lifespan extension and preservation of bone structure. The abstract does not report sample sizes, follow-up beyond the two measurement ages, or whether the bone findings translate to fewer fractures or to humans.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is preclinical mouse data, and the abstract reports no sample sizes, no fracture outcomes and no human evidence. Associations in bone architecture are not established causes of lifespan or healthspan effects.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Dall’Ara E, Sreenivasan D, Oliviero S, Boudiffa M, Miller RA, Juarez M, Bellantuono I. · europepmc.org · June 19, 2026